BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23743928)

  • 1. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.
    Selinger CI; Rogers TM; Russell PA; O'Toole S; Yip P; Wright GM; Wainer Z; Horvath LG; Boyer M; McCaughan B; Kohonen-Corish MR; Fox S; Cooper WA; Solomon B
    Mod Pathol; 2013 Dec; 26(12):1545-53. PubMed ID: 23743928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
    Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
    Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
    Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
    Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
    Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
    Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
    Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.
    Li Y; Pan Y; Wang R; Sun Y; Hu H; Shen X; Lu Y; Shen L; Zhu X; Chen H
    PLoS One; 2013; 8(7):e69016. PubMed ID: 23922677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
    Ilie MI; Bence C; Hofman V; Long-Mira E; Butori C; Bouhlel L; Lalvée S; Mouroux J; Poudenx M; Otto J; Marquette CH; Hofman P
    Ann Oncol; 2015 Jan; 26(1):238-244. PubMed ID: 25344360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
    Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
    Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.
    Hutarew G; Hauser-Kronberger C; Strasser F; Llenos IC; Dietze O
    Histopathology; 2014 Sep; 65(3):398-407. PubMed ID: 24612196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
    Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
    PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
    Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
    Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
    Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.
    Gruber K; Kohlhäufl M; Friedel G; Ott G; Kalla C
    J Thorac Oncol; 2015 Apr; 10(4):713-6. PubMed ID: 25789835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
    Bironzo P; Melocchi L; Monica V; Trebeschi D; Barbieri F; Maiello E; Migliorino MR; Lombardi A; Tiseo M; Righi L; Graziano P; Rossi G; Novello S
    Pathologica; 2022 Aug; 114(4):278-287. PubMed ID: 36083243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer.
    Cutz JC; Craddock KJ; Torlakovic E; Brandao G; Carter RF; Bigras G; Deschenes J; Izevbaye I; Xu Z; Greer W; Yatabe Y; Ionescu D; Karsan A; Jung S; Fraser RS; Blumenkrantz M; Lavoie J; Fortin F; Bojarski A; Côté GB; van den Berghe JA; Rashid-Kolvear F; Trotter M; Sekhon HS; Albadine R; Tran-Thanh D; Gorska I; Knoll JH; Xu J; Blencowe B; Iafrate AJ; Hwang DM; Pintilie M; Gaspo R; Couture C; Tsao MS
    J Thorac Oncol; 2014 Sep; 9(9):1255-63. PubMed ID: 25122422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative analysis of immunohistochemistry and fluorescent
    Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
    Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
    Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
    J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.